MedTrace Logo

A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors

NCT05173142 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2026-05-15

No results posted yet for this study

Summary

A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination with Chemotherapy or Toripalimab in Advanced Solid Tumors

Conditions

Interventions

DRUG

HMPL-453

HMPL-453 administered orally.

DRUG

gemcitabine and cisplatin

Gemcitabine and Cisplatin administered intravenously.

DRUG

toripalimab

Toripalimab administered intravenously.

DRUG

Docetaxel

Docetaxel administered intravenously.

Sponsors & Collaborators

  • Hutchison Medipharma Limited

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-22
Primary Completion
2025-07-17
Completion
2026-01-17

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05173142 on ClinicalTrials.gov